Announcements Trials
Browse Landscape

Phase

Phase 4 3Phase 2 2Phase NA 1Phase EARLY_PHASE1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Vaping 1Tobacco Use Disorder 1Smoking Cessation 1Neoplasms, Second Primary 1Behavior, Addictive 1

Interventions

pembrolizumab 514Specimen Handling 384Carboplatin 372Magnetic Resonance Spectroscopy 337Cisplatin 327Nivolumab 301Cyclophosphamide 297Radiotherapy 255Paclitaxel 255Biopsy 237Gemcitabine 229Bevacizumab 212Dexamethasone 168durvalumab 162Oxaliplatin 159Capecitabine 154Rituximab 153Fluorouracil 148venetoclax 143atezolizumab 142Drug Therapy 140Docetaxel 140Etoposide 139Doxorubicin 132Ipilimumab 124Lenalidomide 119Radiosurgery 118Prednisone 116Leucovorin 112fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Varenicline × 1 year × Clear all
NCT04634071 2026-02-02

TTOP

University of Kentucky

Phase 2 Completed
126 enrolled

Smoking Cessation, Neoplasms, Second Primary, Behavior, Addictive

NCT07040566 2025-12-17

A Trial of Varenicline for E-cigarette Cessation

Yale University

Phase 2 Recruiting
326 enrolled

Vaping, Tobacco Use Disorder

Data powered by HemOnc (CC BY 4.0) Colophon âš¡